Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz to the newly created position of Vice President, Capital Markets Strategy & Investor Relations. Mr. Moskowitz will oversee the Company’s investor relations activities and will also work with the senior leadership team to further develop Verona Pharma’s public market profile.
“We are delighted to welcome David to Verona Pharma,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “His experience and insights make him ideally suited to support our investor relations programme and goals. He will play an instrumental role in forming and implementing our IR strategy as we plan to start Phase 3 trials with first-in-class product candidate, ensifentrine, in 2020.”